Please login to the form below

Not currently logged in
Email:
Password:

Merck expands in emerging markets

Merck has acquired a supplier to the biopharma industry in China as it opens a new technology centre in India

Merck has announced the acquisition of Beijing Skywing Technology, a supplier of cell-culture media products, technical services and bioreactors for the Chinese biopharmaceutical industry.

The deal, worth around €14m, will see German-based Merck take 100 per cent share of the company adding to its presence in China where it currently employs 600 people. The company said it expects the country's biopharmaceutical market to grow by 20 per cent over the next few years.

"The acquisition allows Merck to immediately establish a direct presence in this market segment in China with access to an attractive and innovative cell-culture media portfolio, close relationships to local customers, a skilled management team and a high-quality facility," said Burghard Freiberg, head of the business field pharma chemicals solutions of the Merck Millipore division.

Dr Matthias Bucerius, head of sales Asia, pharma chemicals solutions of the Merck Millipore division, said: "Beijing Skywing Technology is one of the leading players in the cell-culture media market in China with very close business relationships to vaccine manufacturers and an excellent reputation in the local biotech industry."

In addition to this acquisition, Merck also opened a new technology centre in Mumbai, India focusing on research services in both pharmaceuticals and biotechnology. The centre comprises eight laboratories, with the discovery of new biological and chemical entities for use in drug development a key area of research.

Speaking on the opening of the centre, Klaus Bischoff, head of laboratory solutions business unit, Merck Millipore, said: "Supported by over 300 years of experience, the new application and technology centre will be an ideal platform to showcase Merck's capabilities in the high growth fields of biopharmaceutical process solutions and laboratory essentials as well as pigments and cosmetics for our customers in India."

5th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics